The content on this site is intended for healthcare professionals only
Prof Brünner talks to ecancertv at ESMO 2016 about his institute's work looking at new pathways in colorectal cancer.
Biomarkers and screening are a focus, as well as combating drug resistance and drug repurposing.
ecancer's filming at ESMO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.
ctDNA evaluation may play a prognostic role in stage III colon cancer treated with celecoxib
Blood-based test may provide a convenient and effective option for CRC screening in the average-risk U.S. population
Ecobiosocial factors and risk for colorectal cancer cluster: Two- and three-way interactions
New classification for identifying HR myeloma based on cytogenetic abnormalities
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Revolutionising myeloma treatment through immune profiling
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Genomic testing: Awareness and effective communication between healthcare professionals and patients
